Rethinking Clinical Trials

MAY 19, 2023

The team’s goals were to design for the primary care setting because 85% of hypertension care is in this setting. Later this year, the study team will launch the COACH trial, a pragmatic clinical trial with 550 adult primary care patients with uncontrolled hypertension who are portal users.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Rethinking Clinical Trials

SEPTEMBER 22, 2022

The COlchicine Hypertension Trial (COHERENT) is a pragmatic Phase II trial that looked at only hypertension by using registry data to identify patients that receive at least two hypertension drugs. The DECODE trial used registry data to identify patients with chronic kidney disease. Learn more. Read about DANFLU-1.

Trials 130

Trials Cardiology Vaccination Vaccine 130

Rethinking Clinical Trials

FEBRUARY 14, 2024

The study started in June 2016 and ended in June 2022 and ultimately found no difference between the 2 drugs in preventing major CV outcomes and non-cancer death among hypertensive VA patients. The VA IRB determined DCP was a minimal risk study, with less restrictive eligibility criteria and EHR-based safety and outcome monitoring.

Clinical Trials 152

Clinical Trials Clinical Trials Cardiology Trials 152

Rethinking Clinical Trials

FEBRUARY 16, 2023

ICD-Pieces studied patients with chronic kidney disease (CKD), diabetes and hypertension. Tags #pctGR, @Collaboratory1 The post Grand Rounds Ethics and Regulatory Series February 10, 2023: Informing and Consenting: What Are the Goals? (P. The intervention was to facilitate delivery of guideline-based care. Pearl O’Rourke, MD; David S.

Clinical Trials 130

Clinical Trials Clinical Trials Medicine Trials 130

pharmaphorum

DECEMBER 2, 2020

Others rapidly followed, including Glucotrol, aimed at diabetics, and Procardia, an anti-hypertensive. Formulated initially at the Sandwich site in the UK as an anti-hypertensive, it was found have “unexpected” side effects that made the company rapidly change the indication to erectile dysfunction.

Sales 127

Sales Production Drugs Marketing 127

pharmaphorum

DECEMBER 7, 2021

Sildenafil is also sold as Revatio to treat pulmonary artery hypertension (PAH). That finding could provide some comfort to Biogen and Eisai, whose recently-approved amyloid-targeting drug Aduhelm (aducanumab) is struggling to gain traction in the market on the back of unconvincing efficacy data, safety concerns and a high price tag.

Drugs 52

Drugs Clinical Trials Clinical Trials Scientist 52

pharmaphorum

FEBRUARY 26, 2021

The company brought with it a group of medicines that treat pulmonary arterial hypertension – well-established blockbuster Tracleer (bosentan), and the more recently-approved Opsumit (macitentan) and Uptravi (selexipag), as well as a slew of pipeline products. . The post A history of Johnson & Johnson appeared first on.

Sales 124

Sales Production Pharma Companies Marketing 124